AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.
暂无分享,去创建一个
N. Watts | Rachel Pessah-Pollack | N. Binkley | M. McClung | S. Petak | E. Lewiecki | P. Camacho | L. Eldeiry | S. Wimalawansa | Dima L. Diab | D. Hurley | S. T. Harris | Steven M Petak | E. Lewiecki | Nelson B Watts | Neil Binkley | Daniel L Hurley | Rachel Pessah-Pollack | A. Farooki | Jennifer J Kelly | Azeez Farooki | E Michael Lewiecki | Pauline M Camacho | Dima L Diab | Leslie S Eldeiry | Steven T Harris | Jennifer Kelly | Michael McClung | Sunil J Wimalawansa | Leslie S. Eldeiry
[1] E. Guallar,et al. Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes , 2019, Annals of Internal Medicine.
[2] N. Watts,et al. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. , 2019, The Journal of clinical endocrinology and metabolism.
[3] D. Wiebe,et al. IT'S TIME TO STOP PRESCRIBING ERGOCALCIFEROL. , 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[4] Leila C. Kahwati,et al. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.
[5] P. Miller,et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis , 2018, The Journal of clinical endocrinology and metabolism.
[6] A. LaCroix,et al. Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case‐Control Study in the Women's Health Initiative , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] R. Rizzoli,et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis , 2018, The Journal of clinical endocrinology and metabolism.
[8] G. Horowitz,et al. Price of High-Throughput 25-Hydroxyvitamin D Immunoassays: Frequency of Inaccurate Results. , 2018, The journal of applied laboratory medicine.
[9] R. Kumar,et al. Comparison of the effect of daily versus bolus dose maternal vitamin D3 supplementation on the 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 ratio. , 2018, Bone.
[10] R. Adler. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. , 2018, European journal of endocrinology.
[11] N. Binkley,et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE QUALITY OF DXA SCANS AND REPORTS. , 2018, Endocrine Practice.
[12] Jacques P. Brown,et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] S. Wimalawansa. Non-musculoskeletal benefits of vitamin D , 2018, The Journal of Steroid Biochemistry and Molecular Biology.
[14] C. Cooper,et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.
[15] P. Camacho,et al. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[16] P. Geusens,et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.
[17] M. Bech,et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study , 2018, Osteoporosis International.
[18] G. Scambia,et al. The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause , 2017, International journal of endocrinology.
[19] C. Roux,et al. Determinants of short term fracture risk in patients with a recent history of low-trauma non-vertebral fracture. , 2017, Bone.
[20] Jacques P. Brown,et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial , 2017, The Lancet.
[21] A. Grauer,et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.
[22] B. Cortet,et al. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk , 2017, Osteoporosis International.
[23] J. Garber,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY PROTOCOL FOR STANDARDIZED PRODUCTION OF CLINICAL PRACTICE GUIDELINES, ALGORITHMS, AND CHECKLISTS - 2017 UPDATE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[24] Jacques P. Brown,et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. , 2017, The lancet. Diabetes & endocrinology.
[25] R. Eastell,et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability , 2017, Osteoporosis International.
[26] S. Polyzos,et al. Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] N. Watts,et al. Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] C. Roux,et al. Imminent fracture risk , 2017, Osteoporosis International.
[29] D. Hans,et al. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report , 2017, The Journal of clinical endocrinology and metabolism.
[30] D. Dempster,et al. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] Klaus Engelke,et al. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] V. Gudnason,et al. Imminent risk of fracture after fracture , 2017, Osteoporosis International.
[33] W. Leslie,et al. DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk? , 2017, Calcified Tissue International.
[34] Christine L. Taylor,et al. Vitamin D Deficiency - Is There Really a Pandemic? , 2016, The New England journal of medicine.
[35] Yoon-Sok Chung,et al. Trabecular Bone Score (TBS) and TBS-Adjusted Fracture Risk Assessment Tool are Potential Supplementary Tools for the Discrimination of Morphometric Vertebral Fractures in Postmenopausal Women With Type 2 Diabetes. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[36] D. Bauer,et al. Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] J. Melnick,et al. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease , 2016, American Journal of Nephrology.
[38] A. Grauer,et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.
[39] C. Christiansen,et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. , 2016, JAMA.
[40] M. Bonafede,et al. Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data , 2016, Archives of Osteoporosis.
[41] Jacques P. Brown,et al. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates , 2016, The Journal of clinical endocrinology and metabolism.
[42] Jacques P. Brown,et al. A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] C. Gordon,et al. Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[44] K. Michaëlsson,et al. Mortality After Atypical Femoral Fractures: A Cohort Study , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] W. Willett,et al. Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. , 2016, JAMA internal medicine.
[46] D. Bauer,et al. Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[47] D. Black,et al. Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.
[48] N. Watts,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[49] J. Straseski,et al. Performance characteristics of six automated 25-hydroxyvitamin D assays: Mind your 3s and 2s. , 2015, Clinical biochemistry.
[50] C. Weaver,et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation , 2015, Osteoporosis International.
[51] G. Beck,et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. , 2015, The New England journal of medicine.
[52] G. Wells,et al. Does salmon calcitonin cause cancer? A review and meta-analysis , 2015, Osteoporosis International.
[53] R. E. Johnson,et al. Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial. , 2015, JAMA internal medicine.
[54] Hang Lee,et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial , 2015, The Lancet.
[55] C C Glüer,et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. , 2015, Bone.
[56] Jacques P. Brown,et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture , 2015, Menopause.
[57] P. Kannus,et al. Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. , 2015, JAMA internal medicine.
[58] S. Cummings,et al. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON‐Pivotal Fracture Trial (PFT) , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[59] M. Heckman,et al. EFFECTIVENESS AND OUTCOMES OF CURRENT PRACTICE IN TREATING VITAMIN D DEFICIENCY IN PATIENTS LISTED FOR LIVER TRANSPLANTATION. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[60] A. Bockisch,et al. Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[61] F. Harrell,et al. Vitamin D Therapy in Individuals With Prehypertension or Hypertension: The DAYLIGHT Trial , 2015, Circulation.
[62] Jacques P. Brown,et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[63] G. Qian,et al. Vitamin D, parathyroid hormone, and heart failure in a Chinese elderly population. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[64] R. Heaney,et al. Quantifying the vitamin D economy. , 2015, Nutrition reviews.
[65] L. Spangler,et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. , 2015, Mayo Clinic proceedings.
[66] R. Eastell,et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study , 2015, Osteoporosis International.
[67] Y. Shimada,et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide , 2015, Journal of Bone and Mineral Metabolism.
[68] T. López-Cuadrado,et al. Safety of balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures in Europe: a meta-analysis of randomized controlled trials , 2014, European Spine Journal.
[69] B. Dawson-Hughes,et al. The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[70] T. Dodson,et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[71] C. Annweiler,et al. Usefulness of bone density measurement in fallers. , 2014, Joint, bone, spine : revue du rhumatisme.
[72] S. Cummings,et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? , 2014, The Journal of clinical endocrinology and metabolism.
[73] K. Michaëlsson,et al. Risk of atypical femoral fracture during and after bisphosphonate use. , 2014, The New England journal of medicine.
[74] J. Garber,et al. American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists--2014 Update and the AACe G4G Program. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[75] S. Cummings,et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. , 2014, JAMA internal medicine.
[76] R. Buchbinder,et al. Two‐Year Results of a Randomized Placebo‐Controlled Trial of Vertebroplasty for Acute Osteoporotic Vertebral Fractures , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[77] A. McTiernan,et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. , 2014, The American journal of clinical nutrition.
[78] Omar Kreidieh,et al. Impact of changes in mortality on FRAX-derived fracture probabilities. , 2014, Bone.
[79] Ji-Youn Jung,et al. Effect of Water-Soluble Silicon Supplementation on Bone Status and Balance of Calcium and Magnesium in Male Mice , 2014, Biological Trace Element Research.
[80] Heinrich Resch,et al. Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[81] S. Silverman,et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group , 2014, Osteoporosis International.
[82] Hang Lee,et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. , 2014, The Journal of clinical endocrinology and metabolism.
[83] Victoria A Goodwin,et al. Multiple component interventions for preventing falls and fall-related injuries among older people: systematic review and meta-analysis , 2014, BMC Geriatrics.
[84] Haakan Strand,et al. Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review , 2014, Archives of Osteoporosis.
[85] R. Lindsay,et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. , 2014, The Journal of clinical endocrinology and metabolism.
[86] C. Cooper,et al. Worldwide uptake of FRAX , 2014, Archives of Osteoporosis.
[87] Thomas D Brown,et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[88] S. Wimalawansa. Physiology of Calcitonin and Its Therapeutic Uses , 2014 .
[89] T. Raastad,et al. Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway. , 2014, The Journal of clinical endocrinology and metabolism.
[90] J. Aloia,et al. The vitamin d dose response in obesity. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[91] N. Watts,et al. Postmenopausal osteoporosis , 2013, Current Opinion in Endocrinology, Diabetes & Obesity.
[92] D. Bauer. Clinical practice. Calcium supplements and fracture prevention. , 2013, The New England journal of medicine.
[93] Charles R. Evans,et al. Artificial Sweeteners Stimulate Adipogenesis and Suppress Lipolysis Independently of Sweet Taste Receptors* , 2013, The Journal of Biological Chemistry.
[94] Jacques P. Brown,et al. The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension , 2013, The Journal of clinical endocrinology and metabolism.
[95] Jacques P. Brown,et al. Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). , 2013, The Journal of clinical endocrinology and metabolism.
[96] Albert Gollhofer,et al. The Importance of Trunk Muscle Strength for Balance, Functional Performance, and Fall Prevention in Seniors: A Systematic Review , 2013, Sports Medicine.
[97] V. Moyer. Screening for Intimate Partner Violence and Abuse of Elderly and Vulnerable Adults: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.
[98] S. Cummings,et al. Goal‐directed treatment of osteoporosis , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[99] A. Wolk,et al. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study , 2013, BMJ : British Medical Journal.
[100] S. Cummings,et al. Treat-to-target for osteoporosis: is now the time? , 2013, The Journal of clinical endocrinology and metabolism.
[101] J. Shepherd,et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[102] D. Bauer,et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. , 2013, The American journal of medicine.
[103] A. Hardidge,et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. , 2013, Bone.
[104] L. Häberle,et al. Effects of exercise on fracture reduction in older adults , 2013, Osteoporosis International.
[105] J. Manson,et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study , 2012, Osteoporosis International.
[106] M. Aghamirsalim,et al. Do the hospitalized patients with osteoporotic fractures require endocrinologists’ help? , 2012, Journal of Endocrinological Investigation.
[107] W. Kohrt,et al. Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trials , 2012, BMC Musculoskeletal Disorders.
[108] Eugene McCloskey,et al. FRAX updates 2012 , 2012, Current opinion in rheumatology.
[109] S. Silverman,et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges , 2012, Osteoporosis International.
[110] P. Miller,et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial , 2012, Osteoporosis International.
[111] J. Kanis,et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[112] I. Reid,et al. Calcium supplements: bad for the heart? , 2012, Heart.
[113] E. Lespessailles,et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. , 2012, Joint, bone, spine : revue du rhumatisme.
[114] J. Macho,et al. Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures: A 12‐month randomized follow‐up, controlled trial , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[115] S. Silverman,et al. What’s in a name? What constitutes the clinical diagnosis of osteoporosis? , 2012, Osteoporosis International.
[116] A. LaCroix,et al. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[117] S. Cummings,et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[118] Myunghan Choi,et al. Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis. , 2012, Journal of the American Medical Directors Association.
[119] J. Kanis,et al. FRAX underestimates fracture risk in patients with diabetes , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[120] D. Ransohoff,et al. Bone-density testing interval and transition to osteoporosis in older women. , 2012, The New England journal of medicine.
[121] S. Wimalawansa. Vitamin D in the New Millennium , 2012, Current Osteoporosis Reports.
[122] S. Cummings,et al. The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[123] S. Silverman,et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures , 2012, Osteoporosis International.
[124] H. Bang,et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml , 2012, Osteoporosis International.
[125] J. Kanis,et al. FRAX® with and without Bone Mineral Density , 2011, Calcified Tissue International.
[126] C. Luo,et al. Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials , 2011, PloS one.
[127] I. Reid,et al. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. , 2011, The American journal of clinical nutrition.
[128] N. Freemantle,et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.
[129] Giuseppe Guglielmi,et al. Integrated imaging approach to osteoporosis: state-of-the-art review and update. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[130] Jacques P. Brown,et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? , 2011, Osteoporosis International.
[131] T. Brown,et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research , 2011 .
[132] S. Cummings,et al. WHO absolute fracture risk models (FRAX): Do clinical risk factors improve fracture prediction in older women without osteoporosis? , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[133] J. Pearson,et al. Risk communication methods in hip fracture prevention: a randomised trial in primary care. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.
[134] C. Cooper,et al. Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.
[135] P. Heagerty,et al. Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis , 2011, BMJ : British Medical Journal.
[136] R. Eastell,et al. Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[137] R. Russell,et al. Bisphosphonates: the first 40 years. , 2011, Bone.
[138] R. Takayanagi,et al. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis , 2011, Clinical interventions in aging.
[139] C. Gordon,et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.
[140] E. Vittinghoff,et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. , 2011, JAMA.
[141] Rebecca L. Kesman,et al. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. , 2011, The American journal of medicine.
[142] K. Michaëlsson,et al. Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.
[143] A. Avenell,et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis , 2011, BMJ : British Medical Journal.
[144] A. Ross,et al. The 2011 report on dietary reference intakes for calcium and vitamin D , 2011, Public Health Nutrition.
[145] S. Boonen,et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[146] S. Cummings,et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[147] J. S. San Martin,et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. , 2011, The Journal of clinical endocrinology and metabolism.
[148] S. Khosla,et al. Emerging therapeutic opportunities for skeletal restoration , 2011, Nature Reviews Drug Discovery.
[149] JoAnn E. Manson,et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know , 2010, The Journal of clinical endocrinology and metabolism.
[150] S. Schneeweiss,et al. Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[151] B. Clarke,et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis , 2011 .
[152] J. Kanis,et al. High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice , 2011, Osteoporosis International.
[153] J. Kanis,et al. FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. , 2011, Journal of clinical densitometry.
[154] J. Kanis,et al. Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement , 2011, Osteoporosis International.
[155] C. Cooper,et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.
[156] J. Kanis,et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.
[157] Klaus Klaushofer,et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[158] E. Lewiecki. Risk communication and shared decision making in the care of patients with osteoporosis. , 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[159] S. Silverman,et al. The Utility and Limitations of FRAX: A US Perspective , 2010, Current osteoporosis reports.
[160] A. Pinto-Neto,et al. Predictors of falls in women with and without osteoporosis. , 2010, The Journal of orthopaedic and sports physical therapy.
[161] E. Buskens,et al. Percutaneous Vertebroplasty Is Not a Risk Factor for New Osteoporotic Compression Fractures: Results from VERTOS II , 2010, American Journal of Neuroradiology.
[162] Gabriela Czanner,et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort , 2010, BMJ : British Medical Journal.
[163] Liam J. Murray,et al. Exposure to oral bisphosphonates and risk of esophageal cancer. , 2010, JAMA.
[164] A. Avenell,et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis , 2010, BMJ : British Medical Journal.
[165] Christina Bougatsos,et al. Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force , 2010, Annals of Internal Medicine.
[166] A. Sai,et al. Bone: Is screening for secondary causes of osteoporosis worthwhile? , 2010, Nature Reviews Endocrinology.
[167] P. Geusens,et al. Assessment of Individual Fracture Risk: FRAX and Beyond , 2010, Current osteoporosis reports.
[168] M. Hiligsmann,et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[169] J. Simpson,et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. , 2010, JAMA.
[170] Mark S Roberts,et al. Health beliefs about osteoporosis and osteoporosis screening in older women and men , 2010, Health education journal.
[171] S. Cummings,et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[172] Celinda P Evitt,et al. Screening for falls and osteoporosis: prevention practice for the hand therapist. , 2010, Journal of hand therapy : official journal of the American Society of Hand Therapists.
[173] H. Gharib,et al. American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[174] J. Radford. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort , 2010, BDJ.
[175] R. Benjamin,et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma , 2010, Osteoporosis International.
[176] D. Torgerson,et al. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk , 2010, Osteoporosis International.
[177] Terrie E. Kitchner,et al. The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort , 2010, Osteoporosis International.
[178] R. Buchbinder,et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. , 2009, The New England journal of medicine.
[179] William Hollingworth,et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. , 2009, The New England journal of medicine.
[180] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[181] R. Eastell,et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. , 2009, Bone.
[182] J B Wong,et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.
[183] R. Lindsay,et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. , 2009, Fertility and sterility.
[184] R. Vieth. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. , 2009, Anticancer research.
[185] Rong-Sen Yang,et al. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis , 2009, Clinical rehabilitation.
[186] B. Ettinger,et al. Updated fracture incidence rates for the US version of FRAX® , 2009, Osteoporosis International.
[187] Kim Brixen,et al. Hip Fracture Patients at Risk of Second Hip Fracture: A Nationwide Population‐Based Cohort Study of 169,145 Cases During 1977–2001 , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[188] N. Watts,et al. Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[189] Meryl S LeBoff,et al. FRAX Facts , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[190] Eric Cassell,et al. Preparing medical students to become attentive listeners , 2009, Medical teacher.
[191] Supplemental Tables,et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.
[192] J. Kanis,et al. The effects of a FRAX® revision for the USA , 2009, Osteoporosis International.
[193] Sarah E Lamb,et al. Interventions for preventing falls in older people living in the community. , 2009, The Cochrane database of systematic reviews.
[194] B. Steele,et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.
[195] C. Roux,et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience , 2009, Osteoporosis International.
[196] Claus Christiansen,et al. Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[197] R. Cumming,et al. Effective Exercise for the Prevention of Falls: A Systematic Review and Meta‐Analysis , 2008, Journal of the American Geriatrics Society.
[198] K. Albain,et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[199] K. Zhu,et al. Randomized Controlled Trial of the Effects of Calcium With or Without Vitamin D on Bone Structure and Bone‐Related Chemistry in Elderly Women With Vitamin D Insufficiency , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[200] J. S. San Martin,et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.
[201] N. Watts,et al. Assessing response to osteoporosis therapy , 2008, Osteoporosis International.
[202] J. S. San Martin,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.
[203] Laurent Pothuaud,et al. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. , 2008, Bone.
[204] J. Glowacki,et al. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures , 2008, Osteoporosis International.
[205] S. Boonen,et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. , 2008, The Journal of clinical endocrinology and metabolism.
[206] K. Zhu,et al. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. , 2008, The Journal of clinical endocrinology and metabolism.
[207] J. Reginster,et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. , 2008, The Journal of rheumatology.
[208] L. Melton,et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.
[209] P. Barber,et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial , 2008, BMJ : British Medical Journal.
[210] S. Cummings,et al. Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF) , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[211] Christian Roux,et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[212] L. Melton,et al. Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.
[213] S. Boonen,et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2007, The New England journal of medicine.
[214] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[215] S. Silverman,et al. Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[216] Sara Gandini,et al. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.
[217] B. Edwards,et al. Prior Fractures are Common in Patients with Subsequent Hip Fractures , 2007, Clinical orthopaedics and related research.
[218] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[219] S. Boonen,et al. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. , 2007, The Journal of clinical endocrinology and metabolism.
[220] A. Tosteson,et al. Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[221] Jacques P. Brown,et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.
[222] R. Marcus,et al. Osteosarcoma and Teriparatide? , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[223] S. Adami,et al. The acute-phase response after bisphosphonate administration , 1987, Calcified Tissue International.
[224] R. Cumming,et al. Influence of fall related factors and bone strength on fracture risk in the frail elderly , 2007, Osteoporosis International.
[225] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[226] J. Bilezikian. Osteonecrosis of the jaw--do bisphosphonates pose a risk? , 2006, The New England journal of medicine.
[227] E. Lewiecki,et al. Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. , 2006, The Journal of clinical endocrinology and metabolism.
[228] J. Magaziner,et al. Hip fracture and its consequences: differences between men and women. , 2006, The Orthopedic clinics of North America.
[229] E. Barrett-Connor,et al. Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.
[230] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[231] A. LaCroix,et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[232] J. Kalmar,et al. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws , 2006, Annals of Internal Medicine.
[233] A. Wolk,et al. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women , 2006, Osteoporosis International.
[234] D. Bauer,et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. , 2006, The Journal of clinical endocrinology and metabolism.
[235] J. Manson,et al. Calcium plus vitamin D supplementation and the risk of fractures. , 2006, The New England journal of medicine.
[236] M. Drezner,et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2005, Annals of the rheumatic diseases.
[237] Phyllis Butow,et al. A systematic review on communicating with patients about evidence. , 2006, Journal of evaluation in clinical practice.
[238] A. Mariotti,et al. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. , 2006, Journal of the American Dental Association.
[239] D. Ofluoğlu,et al. The effect of calcitonin on β-endorphin levels in postmenopausal osteoporotic patients with back pain , 2006, Clinical Rheumatology.
[240] J. Gerberding,et al. Fatalities and injuries from falls among older adults--United States, 1993-2003 and 2001-2005. , 2006, MMWR. Morbidity and mortality weekly report.
[241] J. Allum,et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? , 2006, Osteoporosis International.
[242] K. Siminoski,et al. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women , 2006, Osteoporosis International.
[243] J. Schousboe,et al. Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice , 2006, Osteoporosis International.
[244] B. Mazières,et al. Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study , 2006, Clinical Rheumatology.
[245] R. Downs,et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. , 2005, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[246] A. Sheehan,et al. Effect of Vitamin A on Fracture Risk , 2005, The Annals of pharmacotherapy.
[247] E. Schwartz,et al. Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[248] L. Palermo,et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. , 2005, The New England journal of medicine.
[249] Dieter Felsenberg,et al. Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[250] A. Silman,et al. Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[251] M. Holick,et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. , 2005, The Journal of clinical endocrinology and metabolism.
[252] Bess Dawson-Hughes,et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.
[253] C. Cooper,et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.
[254] J. Cauley,et al. Hip fracture in women without osteoporosis. , 2005, The Journal of clinical endocrinology and metabolism.
[255] R. Parker,et al. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. , 2005, The Journal of clinical endocrinology and metabolism.
[256] David J Torgerson,et al. Primary care Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3 ) for prevention of fractures in primary care , 2005 .
[257] M. Drezner,et al. Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures , 2005, Osteoporosis International.
[258] H. Genant,et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. , 2005, The Journal of clinical endocrinology and metabolism.
[259] D. Wysowski,et al. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. , 2005, Archives of internal medicine.
[260] C. Cooper,et al. Prevalence and incidence of vertebral deformities , 1993, Osteoporosis International.
[261] Olof Johnell,et al. Alcohol intake as a risk factor for fracture , 2005, Osteoporosis International.
[262] S. Cummings,et al. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial , 2005, Osteoporosis International.
[263] O. Johnell,et al. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture , 2005, Osteoporosis International.
[264] R. Eastell,et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures , 2005, Osteoporosis International.
[265] H. Kroger,et al. Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.
[266] C. Christiansen,et al. Changes in bone density and turnover after alendronate or estrogen withdrawal , 2004, Menopause.
[267] J. Reginster,et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. , 2004, Archives of internal medicine.
[268] Richard Eastell,et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. , 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[269] D. Bauer,et al. Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[270] C. Christiansen,et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[271] G. Sandusky,et al. Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose , 2004, Toxicologic pathology.
[272] H. Bischoff-Ferrari,et al. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. , 2004, The American journal of medicine.
[273] J. Gallagher,et al. The effect of soy protein isolate on bone metabolism , 2004, Menopause.
[274] Bess Dawson-Hughes,et al. Effect of Vitamin D on falls: a meta-analysis. , 2004, JAMA.
[275] J. Rodriguez-Portales,et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.
[276] R. Eastell,et al. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.
[277] M. Dowsett,et al. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. , 2004, The American journal of clinical nutrition.
[278] J. Cauley,et al. Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[279] J. Mechanick,et al. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[280] S. Cummings,et al. BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[281] J. Beitz,et al. Renal failure with the use of zoledronic acid. , 2003, The New England journal of medicine.
[282] A. LaCroix,et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.
[283] J. Finkelstein,et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.
[284] Mary L Bouxsein,et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.
[285] Sheryl Zimmerman,et al. Dementia as a Risk Factor for Falls and Fall Injuries Among Nursing Home Residents , 2003, Journal of the American Geriatrics Society.
[286] B. Ettinger,et al. Early discontinuation of treatment for osteoporosis. , 2003, The American journal of medicine.
[287] R. Eastell,et al. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[288] P. Geusens,et al. Vitamin K1 Supplementation Retards Bone Loss in Postmenopausal Women Between 50 and 60 Years of Age , 2003, Calcified Tissue International.
[289] D. Kaufman. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study , 2003, Pharmacoepidemiology and drug safety.
[290] U. Barzel. Recommended testing in patients with low bone density. , 2003, The Journal of clinical endocrinology and metabolism.
[291] C. Charles,et al. Shared treatment decision making: what does it mean to physicians? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[292] C. Cooper,et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. , 2003, Bone.
[293] M. Bouxsein. Mechanisms of osteoporosis therapy: a bone strength perspective. , 2003, Clinical cornerstone.
[294] G. Dolan,et al. Severe increase in creatinine with hypocalcaemia in thalidomide‐treated myeloma patients receiving zoledronic acid infusions , 2002, British journal of haematology.
[295] J. Gallagher,et al. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. , 2002, The Journal of clinical endocrinology and metabolism.
[296] D. Meier,et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. , 2002, The Journal of clinical endocrinology and metabolism.
[297] Z. Tran,et al. Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.
[298] L. Lenchik,et al. What is the role of serial bone mineral density measurements in patient management? , 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[299] C. Cooper,et al. Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study , 2002, Osteoporosis International.
[300] G. Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. , 2002, Endocrine reviews.
[301] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[302] A. Campbell,et al. Preventing Injuries in Older People by Preventing Falls: A Meta‐Analysis of Individual‐Level Data , 2002, Journal of the American Geriatrics Society.
[303] M. Robertson,et al. Application of a falls prevention program for older people to primary health care practice. , 2002, Preventive medicine.
[304] N. Watts,et al. Combination therapy for postmenopausal osteoporosis , 2002, Clinical endocrinology.
[305] J. Vahle,et al. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety , 2002, Toxicologic pathology.
[306] M. Hochberg,et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.
[307] R. Parker,et al. Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. , 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[308] R. Rizzoli,et al. Protein intake and bone disorders in the elderly. , 2001, Joint, bone, spine : revue du rhumatisme.
[309] Jeffrey M. Hausdorff,et al. Gait variability and fall risk in community-living older adults: a 1-year prospective study. , 2001, Archives of physical medicine and rehabilitation.
[310] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[311] C. Christiansen,et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. , 2001, JAMA.
[312] Susan R. Johnson,et al. Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.
[313] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[314] N. Lane. An update on glucocorticoid-induced osteoporosis. , 2001, Rheumatic diseases clinics of North America.
[315] P Geusens,et al. Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.
[316] R. Goodman,et al. The effect of risedronate on the risk of hip fracture in elderly women. , 2001, The New England journal of medicine.
[317] O. Johnell,et al. The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.
[318] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[319] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[320] P. Delmas,et al. Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[321] C. Rosen,et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. , 2000, The Journal of clinical endocrinology and metabolism.
[322] H. Minne,et al. Effects of a Short‐Term Vitamin D and Calcium Supplementation on Body Sway and Secondary Hyperparathyroidism in Elderly Women , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[323] M. Nevitt,et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. , 2000, Archives of internal medicine.
[324] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[325] M. Dougados,et al. Follow-up of Individual Patients on Two DXA Scanners of the Same Manufacturer , 2000, Osteoporosis International.
[326] R. Recker,et al. Study Subjects and Ordinary Patients , 2000, Osteoporosis International.
[327] A. Galanos,et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. , 1999, The Clinical journal of pain.
[328] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[329] G. Elwyn,et al. How Should Effectiveness of Risk Communication to Aid Patients' Decisions Be Judged? , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[330] P. Delmas,et al. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[331] P. Miller,et al. Discordance in patient classification using T-scores. , 1999, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[332] C. Charles,et al. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. , 1999, Social science & medicine.
[333] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[334] S. Cummings,et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. , 1999, Arthritis and rheumatism.
[335] J Pearson,et al. Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[336] T. Sellers,et al. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. , 1999, American journal of epidemiology.
[337] H. Kemper,et al. The Effect of Exercise Training Programs on Bone Mass: A Meta-analysis of Published Controlled Trials in Pre- and Postmenopausal Women , 1999, Osteoporosis International.
[338] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[339] R. Rizzoli,et al. Protein Supplements Increase Serum Insulin-Like Growth Factor-I Levels and Attenuate Proximal Femur Bone Loss in Patients with Recent Hip Fracture , 1998, Annals of Internal Medicine.
[340] P. Ross,et al. Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[341] Amiram Gafni,et al. Decision-making in the physician-patient encounter , 1998 .
[342] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[343] M S Calvo,et al. Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[344] G. Lyritis,et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. , 1997, Acta orthopaedica Scandinavica. Supplementum.
[345] C. Charles,et al. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). , 1997, Social science & medicine.
[346] B. Drinkwater,et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. , 1997, The American journal of medicine.
[347] P. Galan,et al. Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.
[348] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[349] C Marcelli,et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[350] O. Johnell,et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .
[351] L. Bouter,et al. Vitamin D status and sex hormone binding globulin: Determinants of bone turnover and bone mineral density in elderly women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[352] S. Greenspan,et al. Femoral bone loss progresses with age: A longitudinal study in women over age 65 , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[353] C. Loria,et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. , 1994, Advance data.
[354] H. Spencer,et al. Effect of magnesium on the intestinal absorption of calcium in man. , 1994, Journal of the American College of Nutrition.
[355] E. Barrett-Connor,et al. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. , 1994, JAMA.
[356] S. Cummings,et al. Bone density at various sites for prediction of hip fractures , 1993, The Lancet.
[357] Claus Christiansen,et al. Diagnosis of Osteoporosis , 1992, Southern medical journal.
[358] H K Genant,et al. Axial and appendicular bone density predict fractures in older women , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[359] D. Kiel,et al. Caffeine and the risk of hip fracture: the Framingham Study. , 1990, American journal of epidemiology.
[360] W. Mysiw,et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[361] K. Pun,et al. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. , 1989, Clinical therapeutics.
[362] M. Tinetti,et al. Risk factors for falls among elderly persons living in the community. , 1988, The New England journal of medicine.
[363] H. Daniell. Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. , 1976, Archives of internal medicine.